Medically reviewed by Doru Paul, MD Leukemia is a cancer of the blood-forming tissues that often develops in the bone marrow.

AML: Acute myeloid leukemia; CLL: C-type lectin-like molecule; CXCR: CXC chemokine receptor; N/A: Not applicable; NF: Nuclear factor. Acute myeloid leukemia (AML) remains incurable for the ...

A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...

David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...

Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...

Tuspetinib based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...

Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

LYT-200 exerts its therapeutic effects in AML by killing cancer cells directly via apoptosis and DNA damage as well as reactivating central anti-cancer effectors of the immune system. LYT-200 is the ...